Search results
Showing 736 to 750 of 8917 results
All NICE products on embolism and thrombosis. Includes any guidance, advice and quality standards.
All NICE products on heart failure. Includes any guidance, advice and quality standards.
All NICE products on prostate cancer. Includes any guidance, advice and quality standards.
All NICE products on renal cancer. Includes any guidance, advice and quality standards.
All NICE products on ovarian cancer. Includes any guidance, advice and quality standards.
All NICE products on sarcoma. Includes any guidance, advice and quality standards.
This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS180Show all sections
Sections for QS180
- Quality statements
- Quality statement 1: Referral – chronic open angle glaucoma and related conditions
- Quality statement 2: Referral for cataract surgery
- Quality statement 3: Treatment – late age-related macular degeneration (wet active)
- Quality statement 4: Monitoring late age-related macular degeneration (wet active)
- Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
- Quality statement 6: Certificate of vision impairment
- Update information
In development Reference number: GID-TA11246 Expected publication date: 05 March 2026
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)
NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA867
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA879
NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA910
NICE is unable to make a recommendation on esketamine (Spravato) for treating major depressive disorder in adults at imminent risk of suicide because Janssen did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA899
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)
NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA901
NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA889
NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA884